Rupert Vessey

Insider Reports History

Reporting-owner location: Kalamazoo, MI
Latest reporting-owner signature: /s/ Michael Wolf, Attorney-in-Fact
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Rupert Vessey

Form 4 holding EVP & President, Research

BRISTOL MYERS SQUIBB CO

Security class: Common Stock, $0.10 par value
Shares / value: 47,751
Estimated value: $2,377,045
Report date: 03 May 2023
Price: $49.78
Ownership: Direct

Form 4 holding Director

BIO-TECHNE Corp

Security class: Common Stock
Shares / value: 10,987
Estimated value: $611,206
Report date: 30 Oct 2025
Price: $55.63
Ownership: Direct

Form 4 holding Director

BIO-TECHNE Corp

Security class: Stock Options (Right to Buy)
Shares / value: 3,777
Estimated value: $210,114
Report date: 30 Oct 2025
Price: $55.63
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,777

Form 4 holding EVP & President, Research

BRISTOL MYERS SQUIBB CO

Security class: Common Stock, $0.10 par value
Shares / value: 656
Estimated value: $32,642
Report date: 03 May 2023
Price: $49.78
Ownership: BMS Savings and Investment Program

Form 4 holding Director

Generate Biomedicines, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 29,561
Estimated value
Report date: 26 Feb 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Rupert Vessey

4 GENB

Generate Biomedicines, Inc.

Report period: 26 Feb 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 02 Mar 2026, 18:09
Role: Director
Next action: Open filing details

3 GENB

Generate Biomedicines, Inc.

Report period: 26 Feb 2026
Transactions: 0
Transaction value: $0
Accepted by SEC: 26 Feb 2026, 20:39
Role: Director
Next action: Open filing details

4 TECH

BIO-TECHNE Corp

Report period: 30 Oct 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 03 Nov 2025, 17:23
Role: Director
Next action: Open filing details

4 TECH

BIO-TECHNE Corp

Report period: 24 Oct 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 28 Oct 2024, 16:43
Role: Director
Next action: Open filing details

4 TECH

BIO-TECHNE Corp

Report period: 26 Oct 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 30 Oct 2023, 16:50
Role: Director
Next action: Open filing details

4 BMY

BRISTOL MYERS SQUIBB CO

Report period: 03 May 2023
Transactions: 1
Transaction value: -$3,378,818
Accepted by SEC: 04 May 2023, 17:51
Role: EVP & President, Research
Next action: Open filing details

4 BMY

BRISTOL MYERS SQUIBB CO

Report period: 10 Mar 2023
Transactions: 16
Transaction value: -$2,529,704
Accepted by SEC: 14 Mar 2023, 20:34
Role: EVP & President, Research
Next action: Open filing details

4 BMY

BRISTOL MYERS SQUIBB CO

Report period: 02 Dec 2022
Transactions: 3
Transaction value: -$364,923
Accepted by SEC: 06 Dec 2022, 17:43
Role: EVP, Research & Early Dev.
Next action: Open filing details

4 BMY

BRISTOL MYERS SQUIBB CO

Report period: 07 Nov 2022
Transactions: 11
Transaction value: -$553,852
Accepted by SEC: 09 Nov 2022, 19:38
Role: EVP, Research & Early Dev.
Next action: Open filing details

4 TECH

BIO-TECHNE Corp

Report period: 27 Oct 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 31 Oct 2022, 17:21
Role: Director
Next action: Open filing details

4 BMY

BRISTOL MYERS SQUIBB CO

Report period: 16 Mar 2022
Transactions: 10
Transaction value: -$2,466,361
Accepted by SEC: 18 Mar 2022, 17:50
Role: EVP, Research & Early Dev.
Next action: Open filing details

4 BMY

BRISTOL MYERS SQUIBB CO

Report period: 10 Mar 2022
Transactions: 10
Transaction value: -$598,743
Accepted by SEC: 14 Mar 2022, 21:16
Role: EVP, Research & Early Dev.
Next action: Open filing details

4 BMY

BRISTOL MYERS SQUIBB CO

Report period: 01 Mar 2022
Transactions: 3
Transaction value: -$707,095
Accepted by SEC: 03 Mar 2022, 16:33
Role: EVP, Research & Early Dev.
Next action: Open filing details

4 BMY

BRISTOL MYERS SQUIBB CO

Report period: 04 Feb 2022
Transactions: 3
Transaction value: -$85,267
Accepted by SEC: 08 Feb 2022, 17:10
Role: EVP, Research & Early Dev.
Next action: Open filing details

4 BMY

BRISTOL MYERS SQUIBB CO

Report period: 31 Dec 2021
Transactions: 3
Transaction value: -$1,436,108
Accepted by SEC: 04 Jan 2022, 17:19
Role: EVP, Research & Early Dev.
Next action: Open filing details

4 BMY

BRISTOL MYERS SQUIBB CO

Report period: 16 Dec 2021
Transactions: 2
Transaction value: -$1,196,252
Accepted by SEC: 17 Dec 2021, 16:08
Role: EVP, Research & Early Dev.
Next action: Open filing details

4 BMY

BRISTOL MYERS SQUIBB CO

Report period: 02 Dec 2021
Transactions: 3
Transaction value: -$249,234
Accepted by SEC: 06 Dec 2021, 17:27
Role: EVP, Research & Early Dev.
Next action: Open filing details

4 TECH

BIO-TECHNE Corp

Report period: 28 Oct 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 01 Nov 2021, 16:37
Role: Director
Next action: Open filing details

4 BMY

BRISTOL MYERS SQUIBB CO

Report period: 30 Jul 2021
Transactions: 30
Transaction value: -$1,952,046
Accepted by SEC: 03 Aug 2021, 16:50
Role: EVP, Research & Early Dev.
Next action: Open filing details

4 BMY

BRISTOL MYERS SQUIBB CO

Report period: 08 May 2021
Transactions: 3
Transaction value: -$515,133
Accepted by SEC: 11 May 2021, 16:38
Role: EVP, Research & Early Dev.
Next action: Open filing details

4 BMY

BRISTOL MYERS SQUIBB CO

Report period: 05 May 2021
Transactions: 1
Transaction value: -$1,963,802
Accepted by SEC: 07 May 2021, 16:56
Role: EVP, Research & Early Dev.
Next action: Open filing details

4/A TECH

BIO-TECHNE Corp

Report period: 01 Jul 2019
Transactions: 1
Transaction value: $0
Accepted by SEC: 11 Apr 2025, 16:37
Role: Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .